Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.;Shaare Zedek Scientific Limited;KING'S COLLEGE LONDON
发明人:
GABIZON, Alberto, A.,BARENHOLZ, Yechezkel,SHMEEDA, Hilary,MAHER, John,PARENTE PEREIRA, Ana Catarina
申请号：
DK12746128
公开号：
DK2731591T3
申请日:
2012.07.12
申请国别(地区):
DK
年份:
2020
代理人:
摘要：
The present disclosure provides liposomes comprising a membrane and an intraliposomal aqueous water phase, the membrane comprising at least one liposome forming lipid and the intraliposomal aqueous water phase comprises a salt of a bisphosphonate together with an amphipathic weak base agent (PLAD). An example of a liposome is one comprising co encapsulated in the intraliposomal aqueous water phase N-containing bisphosphonate, such as alendronate, and an anthracycline such as doxorubicin which was shown to increase survival as compared to Doxil or to administrations of liposomal alendronate (PLA) and Doxil (separate liposomes). Such liposomes may carry a targeting moiety exposed at the liposome's outer surface, for example, conjugate of folic acid as a targeting moiety to folate receptor (FT-PLAD). Also provided by the present disclosure is a method of preparing the liposomes and methods of use of the liposomes, at times, in combination with additional active ingredients, such as γδ T-cells.
